GFM
NBIX icon

GF Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

GF Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Sell
1,987
-253
-11% -$37.5K ﹤0.01% 234
2026
Q1 		$295K Buy
2,240
+282
+14% +$37.4K ﹤0.01% 254
2025
Q4 		$278K Sell
1,958
-176
-8% -$25.5K ﹤0.01% 261
2025
Q3 		$300K Sell
2,134
-459
-18% -$62.2K 0.01% 255
2025
Q2 		$326K Hold
2,593
– – 0.01% 283
2025
Q1 		$287K Buy
2,593
+467
+22% +$59.2K 0.01% 291
2024
Q4 		$290K Buy
+2,126
New +$263K 0.01% 258

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GF Fund Management's NBIX Position: Q2 2026 in Review

GF Fund Management reduced its Neurocrine Biosciences (NBIX) stake by 11% in Q2 2026, selling an estimated $37.5K and leaving 1,987 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #234.

GF Fund Management first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • GF Fund Management held 1,987 shares of Neurocrine Biosciences worth $335K as of Q2 2026.
  • GF Fund Management sold 253 Neurocrine Biosciences shares in Q2 2026, an estimated $37.5K.
  • Neurocrine Biosciences made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #234 holding.
  • GF Fund Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.